The recent approvals of new cellular immunotherapy (CI) agents requiring long-term followup to monitor safety and efficacy outcomes calls for rapid implementation of a monitoring system. A standardized outcomes database is one solution. The three Hematopoietic Cell Transplantation (HCT) registries of the Center for International Blood and Marrow Transplant Research (CIBMTR), European Society for Blood and Marrow Transplantation (EBMT), and the Japanese Society for Transplant and Cellular Therapy/Japanese Data Center for Hematopoietic Cell Transplantation (JSTCT/JDCHCT) undertook a project to harmonize CI survey items in 2016, establishing a collaboration between the JSTCT/JDCHCT and CIBMTR to leverage existing resources to develop and maintain a data collection structure to handle data from acquisition through processing. This process culminated in the development of a shared patient registry for research on, as well as post-marketing surveys of, treatments in Japan. The initial focus was on CD19-targeted CAR-T cells, the first commercial product of its kind approved in Japan. All Japanese centers were connected to the registry in 2020. Patient registries consist of real-world data, providing a model for their regulatory use. The collaboration addresses technical barriers to international data sharing, allowing worldwide data utilization by academia, industry, and government.

 In 2021, we surveyed hematologists and pediatric hematologists in the Chugoku region of Japan to determine their opinions and attitudes about the support with education and jobs provided for patients undergoing hematopoietic stem cell transplantation. A questionnaire was sent to 31 doctors in 25 hospitals; 23 (74%) doctors responded. Twelve hospitals (67%) had an employment assistance office, but more than half of them had no consultations during the year. Only three doctors considered themselves to be providing good job support. Seven doctors (41%) had experience with online classes. All hospitals evaluated themselves as providing insufficient support to high school and college students. Only 3 of 17 hematologists (18%) had experience in providing support for education. There were regional differences in the support systems for education and employment. Multiple professions need to cooperate, and relationships among neighborhood institutions must be strengthened, to support all patients, including adolescents and young adults.

 Decline in physical function in the early stages after allogeneic hematopoietic stem cell transplantation is a major problem, and it is important to investigate new rehabilitation methods that can control physical function decline. Belt electrode skeletal muscle electrical stimulation (B-SES) was initiated soon after transplantation in a 49-year-old man. It was possible to introduce B-SES 4 weeks post transplantation without any adverse events, such as infection or internal bleeding. Although the amount of physical activity decreased in the early post-transplant period due to hemorrhagic cystitis, the B-SES implementation rate was 92%. Furthermore, the change in knee extensor strength during the transplant period was 0.37 Nm/kg, which was less than the change we had previously reported before the introduction of B-SES. We believe that the introduction of B-SES in the early post-transplant period may be a new rehabilitation strategy for controlling muscle weakness.

 A 48-years-old man with acute megakaryoblastic leukemia admitted to our hospital. He treated with an induction chemotherapy with idarubicin and cytarabine, and he obtained hematological complete remission after two courses of the therapy. He underwent allogeneic peripheral blood stem cell transplantation (allo-HSCT) from an HLA-matched sibling donor. He received a myeloablative conditioning regimen with busulfan (12.8 mg/kg) and cyclophosphamide (120 mg/kg). Cyclosporine and short-term methotrexate were administered to prevent graft-versus-host disease (GVHD). He developed fever and chest pain on the 8th day after allo-HSCT before neutrophil engraftment. ECG showed ST-segment elevation in Ⅱ, Ⅲ, aVF, V2-V4 and pericardial effusion was observed by echocardiography. He was clinically diagnosed as acute pericarditis. Colchicine was administered for acute pericarditis, and his symptoms rapidly improved. Although there have been known cases of pericarditis after allo-HSCT that usually occur late after allo-HSCT due to irradiation or chronic GVHD, this case was diagnosed as acute pericarditis that developed in the early post-transplant period before the hematopoietic function recovered. Our results suggest that colchicine may be effective in the treatment of acute pericarditis that develops in the early post-transplant period.